

Amendments to the Claims:

Listing of the claims:

This listing of the claims will replace all prior versions, and listing, of the claims in the application:

1. – 48. (Canceled)

49. (New) A method for preventing and/or treating a respiratory syncytial virus (RSV)-induced disease, the method comprising administering to a subject in need thereof a high affinity neutralizing immunoglobulin that specifically binds a RSV antigen with an affinity constant (K_a) of at least $10^{10} M^{-1}$ as measured by surface plasmon resonance.

50. (New) A method for preventing and/or treating a RSV infection, the method comprising administering to a subject in need thereof a high affinity neutralizing immunoglobulin that specifically binds to a RSV antigen with a K_a of at least $10^{10} M^{-1}$ as measured by surface plasmon resonance.

51. (New) The method of claim 49, wherein the K_a is at least $10^{11} M^{-1}$.

52. (New) The method of claim 50, wherein the K_a is at least $10^{11} M^{-1}$.

53. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin has an IC_{50} in a microneutralization assay that is less than the IC_{50} of the reference antibody IX-493.

54. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin has an IC_{50} of 2 $\mu g/ml$ to 10 $\mu g/ml$ in a microneutralization assay.

55. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin specifically binds to a RSV F antigen.

56. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin binds to the same epitope on RSV as the antibody composed of a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO:2 (Figure 1B) and a light chain variable region (VL) having the amino acid sequence SEQ ID NO:1 (Figure 1A).

57. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a VH complementarity determining region (CDR) 1 having the amino acid sequence TAGMSVG (SEQ ID NO:9) or TPGMSVG (SEQ ID NO:10).

58. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a VH CDR 3 having the amino acid sequence SMITNFYFDV (SEQ ID NO:11).

59. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a VL CDR 2 having the amino acid sequence DTFKLAS (SEQ ID NO:12) or DTYKLAS (SEQ ID NO:13).

60. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

61. (New) The method of claim 57, wherein the high affinity neutralizing immunoglobulin further comprises a VH CDR 3 having the amino acid sequence SMITNFYFDV (SEQ ID NO:7).

62. (New) The method of claim 57, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 2 having the amino acid sequence DTFKLAS (SEQ ID NO:12) or DTYKLAS (SEQ ID NO:13).

63. (New) The method of claim 57, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

64. (New) The method of claim 62, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

65. (New) The method of claim 58, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 2 having the amino acid sequence DTFKLAS (SEQ ID NO:12) or DTYKLAS (SEQ ID NO:13).

66. (New) The method of claim 58, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

67. (New) The method of claim 65, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

68. (New) The method of claim 61, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 2 having the amino acid sequence DTFKLAS (SEQ ID NO:12) or DTYKLAS (SEQ ID NO:13).

69. (New) The method of claim 61, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

70. (New) The method of claim 68, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

71. (New) The method of claim 59, wherein the high affinity neutralizing immunoglobulin further comprises a VL CDR 3 having the amino acid sequence of FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

72. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises:

- a. a VH CDR1 having the amino acid sequence TAGMSVG (SEQ ID NO:5) or TPGMSVG (SEQ ID NO:10);
- b. a VH CDR2 having the amino acid sequence DIWWDDKKDYNPSLKS (SEQ ID NO:7);
- c. a VH CDR3 having the amino acid sequence SMITNWYFDV (SEQ ID NO:8) or SMITNFYFDV (SEQ ID NO:11);
- d. a VL CDR1 having the amino acid sequence SASSSVGYMH (SEQ ID NO:3);
- e. a VL CDR2 having the amino acid sequence DTSKLAS (SEQ ID NO:4) or DTFKLAS (SEQ ID NO:12); and
- f. a VL CDR3 having the amino acid sequence FQGSGYPFT (SEQ ID NO: 5), FQGSFYPFT (SEQ ID NO:14), FQGSYYPFT (SEQ ID NO:15) or FQGSWYPFT (SEQ ID NO:16).

73. (New) The method of claim 51 or 52, wherein the high affinity neutralizing immunoglobulin comprises:

- a. a VH CDR1 having the amino acid sequence TAGMSVG (SEQ ID NO:9);
- b. a VH CDR2 having the amino acid sequence DIWWDDKKDYNPSLKS (SEQ ID NO:7);
- c. a VH CDR3 having the amino acid sequence SMITNFYFDV (SEQ ID NO:11);
- d. a VL CDR1 having the amino acid sequence SASSSVGYMH (SEQ ID NO:3);
- e. a VL CDR2 having the amino acid sequence DTFKLAS (SEQ ID NO:12); and
- f. a VL CDR3 having the amino acid sequence FQGSFYPFT (SEQ ID NO: 14) or FQGSYYPFT (SEQ ID NO:15).

74. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an F(ab)'₂, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

75. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin is a humanized antibody.

76. (New) The method of claim 72, wherein the high affinity neutralizing immunoglobulin comprises the framework sequences disclosed in Figure 1, 3, 4, 5, 6 or 7.

77. (New) The method of claim 73, wherein the high affinity neutralizing immunoglobulin comprises the framework sequences disclosed in Figure 1, 3, 4, 5, 6 or 7.

78. (New) The method of claim 72, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an F(ab)'₂, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

79. (New) The method of claim 73, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an F(ab)'₂, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

80. (New) The method of claim of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid sequence of SEQ ID NO:17 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:18.

81. (New) The method of claim of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid sequence of SEQ ID NO:19 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:20.

82. (New) The method of claim of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid

sequence of SEQ ID NO:21 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:22.

83. (New) The method of claim of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:24.

84. (New) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid sequence of SEQ ID NO:25 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:26.

85. (New) The method of claim 49 or 50, wherein the subject is a human.